Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid

Jinong Li, Jing Zhao, Xiaodong Yu, Julie R Lange, Henry Kuerer, Savitri Krishnamurthy, Eric Schilling, Seema A. Khan, Saraswati Sukumar, Daniel Wan-Yui Chan

Research output: Contribution to journalArticle

Abstract

Purpose: To establish a comprehensive proteomic approach for biomarker discovery and validation in breast fluid. Experimental Design: A total of 95 specimens from three institutions were used including 10 nipple aspiration fluid (5 stage I/II cancerous breasts and 5 age-matched healthy controls), 42 ductal lavage fluid from 14 patients with unilateral stage I/II cancer (25 from 9 cancerous breasts and 17 from 7 contralateral breasts), and 42 ductal lavage fluid from 14 high-risk women (multiple ducts repeated lavage). Differentially expressed protein/peptides were discovered by proteomic analysis of training sample, using Protein Chip arrays and surface-enhanced laser desorption ionization (SELDI) time-of-flight mass spectrometry, and validated on independently collected testing samples. After protein identification, ELISA was done to confirm the SELDI findings. Results: We were able to obtain reproducible protein profiles using minimal amount of protein (1 μg) by applying an optimized chip protocol and SELDI. We were able to select cancer-associated biomarkers despite large individual variability by applying both unsupervised and supervised cluster analysis. Furthermore, we were able to train and test candidate biomarkers on independently collected samples and identified one component of a multimarker panel as human neutrophil peptides 1 to 3. Conclusions: Breast fluid is a rich source of breast cancer biomarkers. In combination with high-throughput novel proteomic profiling technology and multicenter study design, markers that are highly specific to breast cancer can be discovered and validated. Our observations also suggest that persistent elevation of human neutrophil peptide in high-risk women may imply early onset of cancer not yet detectable by current detection method. Proof of this hypothesis requires follow-up on a larger study population.

Original languageEnglish (US)
Pages (from-to)8312-8320
Number of pages9
JournalClinical Cancer Research
Volume11
Issue number23
DOIs
StatePublished - Dec 1 2005

Fingerprint

Nipples
Therapeutic Irrigation
Breast
Biomarkers
Breast Neoplasms
Proteomics
Protein Array Analysis
Lasers
Tumor Biomarkers
Proteins
Peptides
Multicenter Studies
Cluster Analysis
Mass Spectrometry
Neoplasms
Neutrophils
Research Design
Enzyme-Linked Immunosorbent Assay
Technology
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. / Li, Jinong; Zhao, Jing; Yu, Xiaodong; Lange, Julie R; Kuerer, Henry; Krishnamurthy, Savitri; Schilling, Eric; Khan, Seema A.; Sukumar, Saraswati; Chan, Daniel Wan-Yui.

In: Clinical Cancer Research, Vol. 11, No. 23, 01.12.2005, p. 8312-8320.

Research output: Contribution to journalArticle

Li, Jinong ; Zhao, Jing ; Yu, Xiaodong ; Lange, Julie R ; Kuerer, Henry ; Krishnamurthy, Savitri ; Schilling, Eric ; Khan, Seema A. ; Sukumar, Saraswati ; Chan, Daniel Wan-Yui. / Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 23. pp. 8312-8320.
@article{6f9c4cf06c83446d855df18e35d210e8,
title = "Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid",
abstract = "Purpose: To establish a comprehensive proteomic approach for biomarker discovery and validation in breast fluid. Experimental Design: A total of 95 specimens from three institutions were used including 10 nipple aspiration fluid (5 stage I/II cancerous breasts and 5 age-matched healthy controls), 42 ductal lavage fluid from 14 patients with unilateral stage I/II cancer (25 from 9 cancerous breasts and 17 from 7 contralateral breasts), and 42 ductal lavage fluid from 14 high-risk women (multiple ducts repeated lavage). Differentially expressed protein/peptides were discovered by proteomic analysis of training sample, using Protein Chip arrays and surface-enhanced laser desorption ionization (SELDI) time-of-flight mass spectrometry, and validated on independently collected testing samples. After protein identification, ELISA was done to confirm the SELDI findings. Results: We were able to obtain reproducible protein profiles using minimal amount of protein (1 μg) by applying an optimized chip protocol and SELDI. We were able to select cancer-associated biomarkers despite large individual variability by applying both unsupervised and supervised cluster analysis. Furthermore, we were able to train and test candidate biomarkers on independently collected samples and identified one component of a multimarker panel as human neutrophil peptides 1 to 3. Conclusions: Breast fluid is a rich source of breast cancer biomarkers. In combination with high-throughput novel proteomic profiling technology and multicenter study design, markers that are highly specific to breast cancer can be discovered and validated. Our observations also suggest that persistent elevation of human neutrophil peptide in high-risk women may imply early onset of cancer not yet detectable by current detection method. Proof of this hypothesis requires follow-up on a larger study population.",
author = "Jinong Li and Jing Zhao and Xiaodong Yu and Lange, {Julie R} and Henry Kuerer and Savitri Krishnamurthy and Eric Schilling and Khan, {Seema A.} and Saraswati Sukumar and Chan, {Daniel Wan-Yui}",
year = "2005",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-05-1538",
language = "English (US)",
volume = "11",
pages = "8312--8320",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid

AU - Li, Jinong

AU - Zhao, Jing

AU - Yu, Xiaodong

AU - Lange, Julie R

AU - Kuerer, Henry

AU - Krishnamurthy, Savitri

AU - Schilling, Eric

AU - Khan, Seema A.

AU - Sukumar, Saraswati

AU - Chan, Daniel Wan-Yui

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose: To establish a comprehensive proteomic approach for biomarker discovery and validation in breast fluid. Experimental Design: A total of 95 specimens from three institutions were used including 10 nipple aspiration fluid (5 stage I/II cancerous breasts and 5 age-matched healthy controls), 42 ductal lavage fluid from 14 patients with unilateral stage I/II cancer (25 from 9 cancerous breasts and 17 from 7 contralateral breasts), and 42 ductal lavage fluid from 14 high-risk women (multiple ducts repeated lavage). Differentially expressed protein/peptides were discovered by proteomic analysis of training sample, using Protein Chip arrays and surface-enhanced laser desorption ionization (SELDI) time-of-flight mass spectrometry, and validated on independently collected testing samples. After protein identification, ELISA was done to confirm the SELDI findings. Results: We were able to obtain reproducible protein profiles using minimal amount of protein (1 μg) by applying an optimized chip protocol and SELDI. We were able to select cancer-associated biomarkers despite large individual variability by applying both unsupervised and supervised cluster analysis. Furthermore, we were able to train and test candidate biomarkers on independently collected samples and identified one component of a multimarker panel as human neutrophil peptides 1 to 3. Conclusions: Breast fluid is a rich source of breast cancer biomarkers. In combination with high-throughput novel proteomic profiling technology and multicenter study design, markers that are highly specific to breast cancer can be discovered and validated. Our observations also suggest that persistent elevation of human neutrophil peptide in high-risk women may imply early onset of cancer not yet detectable by current detection method. Proof of this hypothesis requires follow-up on a larger study population.

AB - Purpose: To establish a comprehensive proteomic approach for biomarker discovery and validation in breast fluid. Experimental Design: A total of 95 specimens from three institutions were used including 10 nipple aspiration fluid (5 stage I/II cancerous breasts and 5 age-matched healthy controls), 42 ductal lavage fluid from 14 patients with unilateral stage I/II cancer (25 from 9 cancerous breasts and 17 from 7 contralateral breasts), and 42 ductal lavage fluid from 14 high-risk women (multiple ducts repeated lavage). Differentially expressed protein/peptides were discovered by proteomic analysis of training sample, using Protein Chip arrays and surface-enhanced laser desorption ionization (SELDI) time-of-flight mass spectrometry, and validated on independently collected testing samples. After protein identification, ELISA was done to confirm the SELDI findings. Results: We were able to obtain reproducible protein profiles using minimal amount of protein (1 μg) by applying an optimized chip protocol and SELDI. We were able to select cancer-associated biomarkers despite large individual variability by applying both unsupervised and supervised cluster analysis. Furthermore, we were able to train and test candidate biomarkers on independently collected samples and identified one component of a multimarker panel as human neutrophil peptides 1 to 3. Conclusions: Breast fluid is a rich source of breast cancer biomarkers. In combination with high-throughput novel proteomic profiling technology and multicenter study design, markers that are highly specific to breast cancer can be discovered and validated. Our observations also suggest that persistent elevation of human neutrophil peptide in high-risk women may imply early onset of cancer not yet detectable by current detection method. Proof of this hypothesis requires follow-up on a larger study population.

UR - http://www.scopus.com/inward/record.url?scp=28544442576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544442576&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1538

DO - 10.1158/1078-0432.CCR-05-1538

M3 - Article

VL - 11

SP - 8312

EP - 8320

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -